- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00863954
Application of Magnetic Fields as Adjunctive Treatment for Type II Diabetes
December 14, 2010 updated by: pico-tesla Magnetic Therapies, LLC
A Controlled Pilot Study of the Application of Magnetic Fields Using the Resonator in Adjunctive Management of Type 2 Diabetes
The purpose of this study is to see if using a device called the Resonator, that puts out a very low electromagnetic field, effects blood glucose and A1c levels in people with Type 2 Diabetes.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The purpose of this pilot study is to determine whether application of magnetic fields generated by the Resonator result in statistically significant reductions in finger stick blood glucose levels, serum glucose and hemoglobin A1c levels.
The study will also investigate any induced changes in serum lipids and liver function tests as indirect markers of insulin resistance.
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Colorado
-
Littleton, Colorado, United States, 80120
- pico-tesla Magnetic Therapies
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Current diagnosis of Type II Diabetes Mellitus with A1c level above the upper limit of normal
- Subject currently performs routine finger stick blood sugar testing
- Subject is ambulatory
- None or stable medication regimen without significant side effects for at least 6 months, willingness and ability to maintain the stable medication regimen throughout the course of the study.
- Hemoglobin A1c levels within a 0.8% range of patient mean A1c level for the last two documented determinations, that must be within 2 years of the baseline testing date.
- Willingness to test finger stick blood sugars according to protocol.
- Willingness to have lab test blood draws performed according to protocol
- Willingness to maintain stable diet and activity regimen for the duration of the study.
- Willing and able to abstain from partaking in any non-essential existing or new treatments to improve serum blood sugar levels.
- Adequate contraceptive measures for female subjects
- Male or female
- Any ethnic group
- Between 21 and 80 years of age
Exclusion Criteria:
- Change in medical regimen within 6 months prior to initiation of study
- Any signs of Type I diabetes
- Active infectious process within 3 weeks of study initiation causing wide fluctuations in finger stick blood sugar level.
- Change in BMI of greater than 6% within a 6 month period prior to study initiation
- Any planned revascularization procedure
- Symptomatic congestive heart failure
- Leg or foot ulceration or open wounds
- Gangrene
- History of intermittent claudication
- Hemodialysis
- Currently being treated for malignancy
- Currently being treated with oral or intravenous catabolic steroids.
- Reported consumption of more than 14 alcoholic drinks per week.
- Pregnant, breast feeding,or planning pregnancy prior to the end of participation.
- Developmental disability or cognitive impairment that would make it difficult for the subject to partake in the clinical study, including adequate comprehension of the informed consent form and ability to record the necessary measurements.
- Uncontrolled hypertension
- Uncontrolled atrial fibrillation or other uncontrolled arrythmias, e.g. tachycardia, bradycardia
- Uncontrolled seizure disorder
- Uncontrolled, unstable, or untreated medical conditions which may significantly impact the subjects health or ability to complete the entire study, in the opinion of the investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Output A
|
comparison of different parameter settings of electromagnetic fields using the Resonator Device
|
Active Comparator: Output B
|
comparison of different parameter settings of electromagnetic fields using the Resonator Device
|
Active Comparator: Output C
|
comparison of different parameter settings of electromagnetic fields using the Resonator Device
|
Active Comparator: Output D
|
comparison of different parameter settings of electromagnetic fields using the Resonator Device
|
Active Comparator: Output E
|
comparison of different parameter settings of electromagnetic fields using the Resonator Device
|
Active Comparator: Output F
|
comparison of different parameter settings of electromagnetic fields using the Resonator Device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Reduction in blood glucose and A1c levels at endpoint compared to start
Time Frame: Start point, 3 months and 6 months
|
Start point, 3 months and 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2009
Primary Completion (Actual)
November 1, 2009
Study Completion (Actual)
November 1, 2009
Study Registration Dates
First Submitted
March 17, 2009
First Submitted That Met QC Criteria
March 17, 2009
First Posted (Estimate)
March 18, 2009
Study Record Updates
Last Update Posted (Estimate)
December 15, 2010
Last Update Submitted That Met QC Criteria
December 14, 2010
Last Verified
December 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 08165-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type II Diabetes Mellitus
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
KeyBioscience AGEli Lilly and Company; Profil Institut für Stoffwechselforschung GmbH; Nordic...TerminatedType II Diabetes MellitusGermany
-
HealthInsightCenter for Technology and Aging; VoxivaUnknownType II Diabetes MellitusUnited States
-
University of PretoriaNestlè Nutrition Institute Africa; South African Sugar AssociationCompletedDiabetes Mellitus, Type II [Non-insulin Dependent Type] [NIDDM Type] UncontrolledSouth Africa
-
University of PrimorskaUniversity of Ljubljana School of Medicine, SloveniaCompletedDiabetes Mellitus Type II,Slovenia
-
Microbio Co LtdCompleted
-
Laboratorios Silanes S.A. de C.V.RecruitingDyslipidemia Associated With Type II Diabetes MellitusMexico
-
EMSRecruitingDyslipidemia Associated With Type II Diabetes MellitusBrazil
-
Daiichi Sankyo, Inc.Daiichi Sankyo Korea Co., Ltd.CompletedDyslipidemia Associated With Type II Diabetes MellitusKorea, Republic of
Clinical Trials on Resonator Device
-
pico-tesla Magnetic Therapies, LLCTerminatedType 2 DiabetesUnited States
-
pico-tesla Magnetic Therapies, LLCWithdrawnOsteoarthritis of the HipUnited States
-
pico-tesla Magnetic Therapies, LLCUnknownQuality of Life | Parkinson's DiseaseUnited States
-
pico-tesla Magnetic Therapies, LLCCompletedParkinson's Disease
-
pico-tesla Magnetic Therapies, LLCCompleted
-
pico-tesla Magnetic Therapies, LLCUnknownAlzheimer's DementiaUnited States
-
pico-tesla Magnetic Therapies, LLCWithdrawn
-
BioNumerik Pharmaceuticals, Inc.Lantern Pharma Inc. became Sponsor of Tavocept (BNP7787) IND 051014 as of...CompletedBreast Neoplasms | Breast Diseases | Metastases, Neoplasm
-
Facet TechnologiesLifeScanCompletedDiabetesUnited States
-
Karolinska InstitutetUnknownDegenerative Disc Disease | Discogenic Low Back PainSweden